Skip to main content
. 2020 Dec 13;23(2):139. doi: 10.3892/mmr.2020.11778

Figure 4.

Figure 4.

RAP2A is a target of miR-381. (A) Binding sequence between RAP2A and miR-381 was predicted using starBase. (B) Luciferase reporter assay showing the luciferase activity of RAP2A-wt and RAP2A-mut in 293T cells transfected with NC mimics or miR-381 mimics. (C) RT-qPCR assay results show that the level of RAP2A is higher in CRC tissues than in normal tissues. RT-qPCR and western blot assays were employed to assess RAP2A expression in Caco-2 and SW480 cells with (D) overexpression of miR-381 and (E) knockdown of FLVCR1-AS1. (F) RT-qPCR and western blot assays were performed to evaluate RAP2A expression in Caco-2 and SW480 cells transfected with miR-NC, miR-381 and miR-381 + pcDNA3.1/FLVCR1-AS1. *P<0.05. (G) Pearson's correlation analysis was used to assess the correlation of miR-381 with FLVCR1-AS1 or RAP2A in CRC tissues. RAP2A, Ras-related protein 2a; miR, microRNA; wt, wild-type; mut, mutant; sh short hairpin; NC, negative control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; FLVCR1-AS1, feline leukemia virus subgroup C receptor 1 antisense RNA 1; CRC, colorectal cancer.